{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:26:22Z","timestamp":1776309982769,"version":"3.50.1"},"reference-count":232,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Primary hyperoxalurias (PHs) are a group of inherited alterations of the hepatic glyoxylate metabolism. PHs classification based on gene mutations parallel a variety of enzymatic defects, and all involve the harmful accumulation of calcium oxalate crystals that produce systemic damage. These geographically widespread rare diseases have a deep impact in the life quality of the patients. Until recently, treatments were limited to palliative measures and kidney\/liver transplants in the most severe forms. Efforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a siRNA product against glycolate oxidase, which has become the first effective therapy to treat PH1. However, small molecule drugs have classically been preferred since they benefit from experience and have better pharmacological properties. The development of small molecule inhibitors designed against key enzymes of glyoxylate metabolism is on the focus of research. Enzyme inhibitors are successful and widely used in several diseases and their pharmacokinetic advantages are well known. In PHs, effective enzymatic targets have been determined and characterized for drug design and interesting inhibitory activities have been achieved both in vitro and in vivo. This review describes the most recent advances towards the development of small molecule enzyme inhibitors in the treatment of PHs, introducing the multi-target approach as a more effective and safe therapeutic option.<\/jats:p>","DOI":"10.3390\/jpm11020074","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T12:20:26Z","timestamp":1611750026000},"page":"74","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7212-9880","authenticated-orcid":false,"given":"Maria Dolores","family":"Moya-Garzon","sequence":"first","affiliation":[{"name":"Departamento de Qu\u00edmica Farmac\u00e9utica y Org\u00e1nica, Facultad de Farmacia, Campus de Cartuja s\/n, 18071 Granada, Spain"},{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA"},{"name":"Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0937-698X","authenticated-orcid":false,"given":"Jose Antonio","family":"Gomez-Vidal","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Farmac\u00e9utica y Org\u00e1nica, Facultad de Farmacia, Campus de Cartuja s\/n, 18071 Granada, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-4628","authenticated-orcid":false,"given":"Alfonso","family":"Alejo-Armijo","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Inorg\u00e1nica y Org\u00e1nica, Facultad de Ciencias Experimentales, Campus de Excelencia Internacional Agroalimentario (ceiA3), Universidad de Ja\u00e9n, 23071 Ja\u00e9n, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-8535","authenticated-orcid":false,"given":"Joaquin","family":"Altarejos","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Inorg\u00e1nica y Org\u00e1nica, Facultad de Ciencias Experimentales, Campus de Excelencia Internacional Agroalimentario (ceiA3), Universidad de Ja\u00e9n, 23071 Ja\u00e9n, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan Roberto","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[{"name":"Programa de Medicina Regenerativa, CIMA Universidad de Navarra, 31008 Pamplona, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Navarra, IdiSNA, 31008 Pamplona, Spain"}]},{"given":"Miguel Xavier","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Instituto Universitario de Bio-Org\u00e1nica \u201cAntonio Gonz\u00e1lez\u201d, Instituto de Tecnolog\u00edas Biom\u00e9dicas, Universidad de La Laguna, 38206 La Laguna, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-9854","authenticated-orcid":false,"given":"Eduardo","family":"Salido","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias &amp; Center for Rare Diseases (CIBERER), 38320 Tenerife, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-7873","authenticated-orcid":false,"given":"Sofia","family":"Salido","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Inorg\u00e1nica y Org\u00e1nica, Facultad de Ciencias Experimentales, Campus de Excelencia Internacional Agroalimentario (ceiA3), Universidad de Ja\u00e9n, 23071 Ja\u00e9n, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-7231","authenticated-orcid":false,"given":"Monica","family":"Diaz-Gavilan","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Farmac\u00e9utica y Org\u00e1nica, Facultad de Farmacia, Campus de Cartuja s\/n, 18071 Granada, Spain"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary Hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","article-title":"Primary hyperoxalurias: Disorders of glyoxylate detoxification","volume":"1822","author":"Salido","year":"2012","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_4","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (2020, December 11). Primary Hyperoxaluria Type 1, Gene Reviews, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1283\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","article-title":"The primary hyperoxalurias","volume":"75","author":"Hoppe","year":"2009","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria Type 1: Indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mt.2015.224","article-title":"Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I","volume":"24","author":"Salido","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/mt.2016.4","article-title":"Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1","volume":"24","author":"Dutta","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","article-title":"Mutations inHAO1encoding glycolate oxidase cause isolated glycolic aciduria","volume":"51","author":"Frishberg","year":"2014","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"McGregor, T.L., Hunt, K.A., Nioi, P., Mason, D., Ticau, S., Pelosi, M., Loken, P.R., Finer, S., Griffiths, C.J., and MacArthur, D.G. (2019). Deep Phenotyping of a Healthy Human HAO1 Knockout Informs Therapeutic Development for Primary Hyperoxaluria Type 1. bioRxiv, 524256.","DOI":"10.1101\/524256"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"McGregor, T.L., Hunt, K.A., Yee, E., Mason, D., Nioi, P., Ticau, S., Pelosi, M., Loken, P.R., Finer, S., and Lawlor, D.A. (2020). Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. eLife, 9.","DOI":"10.7554\/eLife.54363"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt0918-777","article-title":"Alnylam launches era of RNAi drugs","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"(2020). Second RNAi drug approved. Nat. Biotechnol., 38, 385.","DOI":"10.1038\/s41587-020-0494-3"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/acs.bioconjchem.0c00268","article-title":"Investigational Therapies for Primary Hyperoxaluria","volume":"31","author":"Kletzmayr","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2016.50","article-title":"siRNA Therapeutics for Primary Hyperoxaluria: A Beginning","volume":"24","author":"Milliner","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101467","DOI":"10.1016\/j.scr.2019.101467","article-title":"Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1","volume":"38","author":"Blouin","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bbrc.2019.07.109","article-title":"Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR\/Cas9 technology","volume":"517","author":"Blouin","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.kint.2020.04.049","article-title":"CRISPR\/Cas9\u2013mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1","volume":"98","author":"Zheng","year":"2020","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000085410","article-title":"Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: A rational gene therapy for primary hyperoxaluria-1 (PH-1)","volume":"25","author":"Koul","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1073\/pnas.0607218103","article-title":"Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer","volume":"103","author":"Salido","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","article-title":"Phenotypic Correction of a Mouse Model for Primary Hyperoxaluria With Adeno-associated Virus Gene Transfer","volume":"19","author":"Salido","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","article-title":"Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1","volume":"23","author":"Castello","year":"2016","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20140250","article-title":"The consensus-based approach for gene\/enzyme replacement therapies and crystallization strategies: The case of human alanine\u2013glyoxylate aminotransferase","volume":"462","author":"Yunta","year":"2014","journal-title":"Biochem. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nano.2016.12.011","article-title":"Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I","volume":"13","author":"Roncador","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/nat.2018.0740","article-title":"Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1","volume":"29","author":"Kukreja","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","article-title":"Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1","volume":"111","author":"Miyata","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2174\/1389450117666160302095254","article-title":"Natural and Unnatural Compounds Rescue Folding Defects of Human Alanine: Glyoxylate Aminotransferase Leading to Primary Hyperoxaluria Type I","volume":"17","author":"Oppici","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/2472555217689992","article-title":"Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease","volume":"22","author":"Hou","year":"2017","journal-title":"SLAS Discov. Adv. Life Sci. R D"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yang, H., Male, M., Li, Y., Wang, N., Zhao, C., Jin, S., Jin, S., Chen, Z., Zhang, X., and Xu, H. (2018). Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0980-8"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1042\/BCJ20190507","article-title":"Cycloserine enantiomers are reversible inhibitors of human alanine:glyoxylate aminotransferase: Implications for Primary Hyperoxaluria type 1","volume":"476","author":"Dindo","year":"2019","journal-title":"Biochem. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1523-1755.2005.00267.x","article-title":"Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele","volume":"67","author":"Monico","year":"2005","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-017-0105-8","article-title":"Correlation between the molecular effects of mutations at the dimer interface of alanine\u2013glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6","volume":"41","author":"Dindo","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1093\/hmg\/ddv276","article-title":"Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I","volume":"24","author":"Oppici","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acschembio.5b00480","article-title":"The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I","volume":"10","author":"Oppici","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0009-8981(95)06149-5","article-title":"Aminooxy acetic acid: A selective inhibitor of alanine:glyoxylate aminotransferase and its use in the diagnosis of primary hyperoxaluria type I","volume":"243","author":"Wanders","year":"1995","journal-title":"Clin. Chim. Acta"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/BJ20141159","article-title":"Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria","volume":"466","author":"Summitt","year":"2015","journal-title":"Biochem. J."},{"key":"ref_37","unstructured":"Lowther, T., and Holmes, R. (2017). Combinations for the Treatment of Kidney Stones. (WO2017100268 (A1)), U.S. Patent."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.2017040390","article-title":"Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria","volume":"29","author":"Fargue","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"165633","DOI":"10.1016\/j.bbadis.2019.165633","article-title":"The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria","volume":"1866","author":"Buchalski","year":"2020","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_40","unstructured":"Querbes, W., Fitzgerald, K., Bettencourt, B., Liebow, A., and Erbe, D. (2016). Compositions and Methods for Inhibition of Hao1 (Hy-droxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression. (WO2016057893 (A1)), U.S. Patent."},{"key":"ref_41","unstructured":"Erbe, D. (2019). Methods for Inhibition of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase) Gene Expression. (WO2019014491 (A1)), U.S. Patent."},{"key":"ref_42","unstructured":"Brown, B., and Dudek, H. (2015). Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (Hao1) by Dou-ble-Stranded Rna. (WO2015100436 (A1)), U.S. Patent."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbadis.2015.12.001","article-title":"Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase","volume":"1862","author":"Li","year":"2016","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria","volume":"28","author":"Liebow","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_46","unstructured":"Davey, R., Jantz, D., Smith, J.J., and Owens, G. (2020). Genetic Modification of the Hydroxyacid Oxidase 1 Gene for Treatment of Primary Hyperoxaluria. (WO2020132659 (A1)), U.S. Patent."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"srep34060","DOI":"10.1038\/srep34060","article-title":"High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_48","unstructured":"Lowther, W.T., and Holmes, R.P. (2017). Glycolate Oxidase Inhibitors and Methods of Use for the Treatment of Kidney Stones. (WO2017100266 (A1)), U.S. Patent."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1021\/acs.jmedchem.8b00399","article-title":"Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1","volume":"61","author":"Romera","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_50","unstructured":"Wang, B., and Chao, Q. (2019). Glycolate Oxidase Inhibitors for the Treatment of Disease. (WO2019133770 (A2)), U.S. Patent."},{"key":"ref_51","unstructured":"Maag, H., Fernandes, M.X., Zamboni, R., Akbariromani, E., Beaulieu, M.-A., Leblanc, Y., and Thakur, P. (2020). Triazole Glycolate Oxidase Inhibitors. (WO2020010309 (A1)), U.S. Patent."},{"key":"ref_52","unstructured":"Lowther, W.T., and Holmes, R.P. (2016). Hypdh Inhibitors and Methods of Use for the Treatment of Kidney Stones. (WO2016123012 (A1)), U.S. Patent."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1172\/JCI128709","article-title":"Lactate dehydrogenase 5: Identification of a druggable target to reduce oxaluria","volume":"129","author":"Stevens","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MNH.0000000000000621","article-title":"Stiripentol identifies a therapeutic target to reduce oxaluria","volume":"29","author":"Letavernier","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria","volume":"26","author":"Lai","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.bbadis.2019.04.017","article-title":"Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity","volume":"1865","author":"Wood","year":"2019","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","article-title":"Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning","volume":"129","author":"Huguet","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000151395","article-title":"Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria","volume":"29","author":"Grujic","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2164(10)72003-7","article-title":"Chapter 3\u2014Oxalate-Degrading Bacteria of the Human Gut as Probiotics in the Management of Kidney Stone Disease","volume":"Volume 72","author":"Laskin","year":"2010","journal-title":"Advances in Applied Microbiology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/1574-6976.12021","article-title":"Genomic and phenotypic evidence for probiotic influences ofLactobacillus gasserion human health","volume":"37","author":"Selle","year":"2013","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00240-016-0952-z","article-title":"The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man","volume":"45","author":"Whittamore","year":"2017","journal-title":"Urolithiasis"},{"key":"ref_62","unstructured":"Russ, Z., Whitaker, W., Deloache, W., and Stanley, S.E. (2020). Methods and Compositions for Treating Hyperoxaluria. (WO2020123483 (A1)), U.S. Patent."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00240-014-0728-2","article-title":"Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria","volume":"43","author":"Kostovcikova","year":"2015","journal-title":"Urolithiasis"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chamberlain, C.A., Hatch, M., and Garrett, T.J. (2019). Metabolomic profiling of oxalate-degrading probiotic Lactobacillus acidophilus and Lactobacillus gasseri. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222393"},{"key":"ref_65","first-page":"G461","article-title":"Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization withOxalobacter","volume":"300","author":"Hatch","year":"2011","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2016020132","article-title":"Oxalobacter formigenes\u2013Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells","volume":"28","author":"Arvans","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00467-019-04463-9","article-title":"Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis","volume":"35","author":"Pape","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.14840","article-title":"Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: A case-control study","volume":"125","author":"Tavasoli","year":"2020","journal-title":"BJU Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00240-017-0998-6","article-title":"A randomised Phase II\/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria","volume":"46","author":"Milliner","year":"2018","journal-title":"Urolithiasis"},{"key":"ref_70","first-page":"908","article-title":"Targeting kidney inflammation as a new therapy for primary hyperoxaluria?","volume":"34","author":"Hoppe","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"F137","DOI":"10.1152\/ajprenal.00047.2019","article-title":"Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-\u03b3-miR-23 axis","volume":"317","author":"Chen","year":"2019","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.kint.2016.03.035","article-title":"An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice","volume":"90","author":"Bartok","year":"2016","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI63679","article-title":"Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1\u03b2 secretion","volume":"123","author":"Mulay","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1681\/ASN.2016040486","article-title":"Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease","volume":"28","author":"Mulay","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/cs0680369","article-title":"Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo","volume":"68","author":"Norman","year":"1985","journal-title":"Clin. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MNH.0000000000000330","article-title":"Molecular modifiers of kidney stones","volume":"26","author":"Alamani","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Steiger, S., Grill, J.F., Ma, Q., B\u00e4uerle, T., Jordan, J., Smolle, M., B\u00f6hland, C., Lech, M., and Anders, H.-J. (2018). Anti-Transforming Growth Factor \u03b2 IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00619"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1903337","DOI":"10.1002\/advs.201903337","article-title":"Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies","volume":"7","author":"Kletzmayr","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0968-0004(99)01533-9","article-title":"Flavoenzymes: Diverse catalysts with recurrent features","volume":"25","author":"Fraaije","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tibs.2006.03.003","article-title":"To be or not to be an oxidase: Challenging the oxygen reactivity of flavoenzymes","volume":"31","author":"Mattevi","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1021\/bi701710r","article-title":"Active Site and Loop 4 Movements within Human Glycolate Oxidase: Implications for Substrate Specificity and Drug Design","volume":"47","author":"Murray","year":"2008","journal-title":"Biochemistry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.abb.2007.06.021","article-title":"Purification and characterization of recombinant human liver glycolate oxidase","volume":"465","author":"Vignaud","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0021-9258(18)66228-3","article-title":"Oxidation and Reduction of Glycolic and Glyoxylic Acids in Plants I. Glycolic Acid Oxidase","volume":"201","author":"Zelitch","year":"1953","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7403","DOI":"10.1016\/S0021-9258(18)50333-1","article-title":"Preliminary Crystallographic Data for Glycolate Oxidase from Spinach","volume":"254","author":"Lindqvist","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/pro.5560060506","article-title":"Three-dimensional structures of glycolate oxidase with bound active-site inhibitors","volume":"6","author":"Stenberg","year":"1997","journal-title":"Protein Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1093\/jxb\/erw090","article-title":"Photorespiratory glycolate\u2013glyoxylate metabolism","volume":"67","author":"Dellero","year":"2016","journal-title":"J. Exp. Bot."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1104\/pp.41.10.1623","article-title":"Increased Rate of Net Photosynthetic Carbon Dioxide Uptake Caused by the Inhibition of Glycolate Oxidase","volume":"41","author":"Zelitch","year":"1966","journal-title":"Plant Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e0130","DOI":"10.1199\/tab.0130","article-title":"Photorespiration","volume":"8","author":"Peterhansel","year":"2010","journal-title":"Arab. Book"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0021-9258(18)55813-0","article-title":"A Study on the Metabolism of Glyoxal in vitro","volume":"194","author":"Kun","year":"1952","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9258(18)65451-1","article-title":"The Oxidation of Glycolic Acid by a Liver Enzyme","volume":"210","author":"Kun","year":"1954","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0005-2744(71)90003-9","article-title":"Purification and characterization of glycolic acid oxidase from pig liver","volume":"227","author":"Schuman","year":"1971","journal-title":"Biochim. Biophys. Acta Enzym."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0021-9258(19)73973-8","article-title":"L-\u03b1-Hydroxy Acid Oxidases of Hog Renal Cortex","volume":"237","author":"Robinson","year":"1962","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1021\/bi00580a023","article-title":"Purification and characterization of human liver glycolate oxidase. Molecular weight, subunit, and kinetic properties","volume":"18","author":"Schwam","year":"1979","journal-title":"Biochemistry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0167-4781(00)00161-5","article-title":"Identification and expression of a cDNA for human glycolate oxidase","volume":"1493","author":"Williams","year":"2000","journal-title":"Biochim. Biophys. Acta BBA Gene Struct. Expr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1074\/jbc.275.17.12590","article-title":"Identification and Characterization of HAOX1, HAOX2, and HAOX3, Three Human Peroxisomal 2-Hydroxy Acid Oxidases","volume":"275","author":"Jones","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1074\/jbc.M109.040063","article-title":"Involvement of Ionizable Groups in Catalysis of Human Liver Glycolate Oxidase","volume":"284","author":"Pennati","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1107\/S1744309109041670","article-title":"Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole","volume":"65","author":"Bourhis","year":"2009","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.biochi.2012.02.003","article-title":"High resolution crystal structure of rat long chain hydroxy acid oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1, 2, 3-thiadiazole. Implications for inhibitor specificity and drug design","volume":"94","author":"Chen","year":"2012","journal-title":"Biochimie"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/jm00192a002","article-title":"Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids","volume":"22","author":"Randall","year":"1979","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/jm00362a020","article-title":"Inhibitors of glycolic acid oxidase. 4-Substituted-2,4-dioxobutanoic acid derivatives","volume":"26","author":"Williams","year":"1983","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/jm00359a015","article-title":"Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives","volume":"26","author":"Rooney","year":"1983","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2220\/biomedres.21.139","article-title":"Effects of D,L-2-Hydroxy-3-Butynoic Acid, an Inhibitor of Glycolate Oxidase, on Oxalogenesis from Glycolate in vivo","volume":"21","author":"Kameda","year":"2000","journal-title":"Biomed. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJM196310172691601","article-title":"Studies on Primary Hyperoxaluria","volume":"269","author":"Frederick","year":"1963","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijbiomac.2011.03.016","article-title":"Exploring glycolate oxidase (GOX) as an antiurolithic drug target: Molecular modeling and in vitro inhibitor study","volume":"49","author":"Shirfule","year":"2011","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1517\/13543784.2010.524205","article-title":"Pharmacological small molecules for the treatment of lysosomal storage disorders","volume":"19","author":"Smid","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_106","unstructured":"Fernandes, M.X., and Maag, H. (2019). Glycolate Oxidase Inhibitors and Use Thereof. (WO2019133813 (A1)), U.S. Patent."},{"key":"ref_107","unstructured":"(2020, December 11). BridgeBio|Pipeline. Available online: https:\/\/bridgebio.com\/pipeline."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2174\/092986710790416263","article-title":"Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials","volume":"17","author":"Granchi","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4155\/fmc.13.206","article-title":"Inhibition of lactate dehydrogenase activity as an approach to cancer therapy","volume":"6","author":"Fiume","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.drudis.2018.05.014","article-title":"Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH) 5 inhibitors","volume":"23","author":"Zhang","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/fmc.13.151","article-title":"Small-molecule inhibitors of human LDH5","volume":"5","author":"Granchi","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/1097-0134(20010501)43:2<175::AID-PROT1029>3.0.CO;2-#","article-title":"Structural Basis for Altered Activity of M- and H-Isozyme Forms of Human Lactate Dehydrogenase","volume":"43","author":"Read","year":"2001","journal-title":"Proteins"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1107\/S1399004714005422","article-title":"Structural characterization of the apo form and NADH binary complex of human lactate dehydrogenase","volume":"70","author":"Dempster","year":"2014","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1107\/S1399004714024791","article-title":"Structures of lactate dehydrogenase A (LDHA) in apo, ternary and inhibitor-bound forms","volume":"71","author":"Kolappan","year":"2015","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Poli, G., Granchi, C., Aissaoui, M., Minutolo, F., and Tuccinardi, T. (2017). Three-Dimensional Analysis of the Interactions between hLDH5 and Its Inhibitors. Molecules, 22.","DOI":"10.3390\/molecules22122217"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Shi, Y., and Pinto, B.M. (2014). Human Lactate Dehydrogenase a Inhibitors: A Molecular Dynamics Investigation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086365"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00894-015-2675-4","article-title":"Screening of novel inhibitors targeting lactate dehydrogenase A via four molecular docking strategies and dynamics simulations","volume":"21","author":"Sun","year":"2015","journal-title":"J. Mol. Model."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4155\/fmc-2019-0287","article-title":"Structural and functional regulation of lactate dehydrogenase-A in cancer","volume":"12","author":"Woodford","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bmb.20849","article-title":"Proteopedia: Rossmann fold: A beta-alpha-beta fold at dinucleotide binding sites","volume":"43","author":"Hanukoglu","year":"2015","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1529\/biophysj.107.109397","article-title":"Lactate Dehydrogenase Undergoes a Substantial Structural Change to Bind its Substrate","volume":"93","author":"Qiu","year":"2007","journal-title":"Biophys. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-017-0045-3","article-title":"Molecular therapy of primary hyperoxaluria","volume":"40","author":"Torres","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0009-8981(88)90359-2","article-title":"Lactate Dehydrogenase M-Subunit Deficiency: A New Type of Hereditary Exertional Myopathy","volume":"173","author":"Kanno","year":"1988","journal-title":"Clin. Chim. Acta"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1515\/med-2019-0077","article-title":"MiR-638 repressed vascular smooth muscle cell glycolysis by targeting LDHA","volume":"14","author":"Chen","year":"2019","journal-title":"Open Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaa1299","article-title":"Targeting LDH enzymes with a stiripentol analog to treat epilepsy","volume":"347","author":"Sada","year":"2015","journal-title":"Science"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"dmm041954","DOI":"10.1242\/dmm.041954","article-title":"FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity","volume":"13","author":"Krishnamoorthy","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"L1305","DOI":"10.1152\/ajplung.00058.2015","article-title":"Pharmacologic inhibition of lactate production prevents myofibroblast differentiation","volume":"309","author":"Kottmann","year":"2015","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Judge, J.L., Nagel, D.J., Owens, K.M., Rackow, A.R., Phipps, R.P., Sime, P.J., and Kottmann, R.M. (2018). Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197936"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"115584","DOI":"10.1016\/j.bone.2020.115584","article-title":"Inhibition of glycolysis by targeting lactate dehydrogenase A facilitates hyaluronan synthase 2 synthesis in synovial fibroblasts of temporomandibular joint osteoarthritis","volume":"141","author":"Li","year":"2020","journal-title":"Bone"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2049-3002-1-19","article-title":"Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells","volume":"1","author":"Billiard","year":"2013","journal-title":"Cancer Metab."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wang, Z., Wang, N., Han, S., Wang, N., Mo, F., Loo, T.Y., Shen, J., Huang, H., and Chen, J. (2013). Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056631"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Liu, Y.-L., Fan, X.-Y., Wang, A.-D., Xia, Y.-Z., Fu, W.-R., Liu, J.-Y., Jiang, F.-L., and Liu, Y. (2019). LDHA suppression altering metabolism inhibits tumor progress by an organic arsenical. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246239"},{"key":"ref_134","first-page":"1","article-title":"A Novel Lactate Dehydrogenase Inhibitor, 1-(Phenylseleno)-4-(Trifluoromethyl) Benzene, Suppresses Tumor Growth through Apoptotic Cell Death","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Amr, A.E.-G.E., Mageid, R.E.A., El-Naggar, M., Naglah, A.M., Nossier, E.S., and Elsayed, E.A. (2020). Chiral Pyridine-3,5-bis-(L-phenylalaninyl-L-leucinyl) Schiff Base Peptides as Potential Anticancer Agents: Design, Synthesis, and Molecular Docking Studies Targeting Lactate Dehydrogenase-A. Molecules, 25.","DOI":"10.3390\/molecules25051096"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1073\/pnas.0914433107","article-title":"Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression","volume":"107","author":"Le","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1016\/j.ejmech.2011.08.046","article-title":"N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation","volume":"46","author":"Granchi","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/jm101007q","article-title":"Discovery ofN-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells","volume":"54","author":"Granchi","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/bjc.2013.681","article-title":"Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia","volume":"110","author":"Maftouh","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11306-014-0672-8","article-title":"Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells","volume":"11","author":"Lu","year":"2015","journal-title":"Metabolomics"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"23218","DOI":"10.1039\/C5RA27736A","article-title":"Discovery of a novel human lactate dehydrogenase A (LDHA) inhibitor as an anti-proliferation agent against MIA PaCa-2 pancreatic cancer cells","volume":"6","author":"Sun","year":"2016","journal-title":"RSC Adv."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nchembio.2143","article-title":"Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition","volume":"12","author":"Boudreau","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/acsmedchemlett.6b00190","article-title":"Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice","volume":"7","author":"Purkey","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejmech.2019.05.033","article-title":"Development of novel human lactate dehydrogenase a inhibitors: High-throughput screening, synthesis, and biological evaluations","volume":"177","author":"Zhou","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10984","DOI":"10.1021\/acs.jmedchem.0c00916","article-title":"Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties","volume":"63","author":"Rai","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bpa.12299","article-title":"The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor","volume":"26","author":"Valvona","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cmdc.201100471","article-title":"Galloflavin (CAS 568-80-9): A Novel Inhibitor of Lactate Dehydrogenase","volume":"7","author":"Manerba","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1016\/j.bmcl.2016.06.083","article-title":"Discovery of 2-((3-cyanopyridin-2-yl)thio)acetamides as human lactate dehydrogenase A inhibitors to reduce the growth of MG-63 osteosarcoma cells: Virtual screening and biological validation","volume":"26","author":"Cui","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.biopha.2016.04.029","article-title":"Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma","volume":"81","author":"Gao","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1039\/C7MD00222J","article-title":"Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells","volume":"8","author":"Fang","year":"2017","journal-title":"MedChemComm"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.bmcl.2018.05.052","article-title":"Computer-aided discovery and biological characterization of human lactate dehydrogenase 5 inhibitors with anti-osteosarcoma activity","volume":"28","author":"Cao","year":"2018","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1039\/C6MD00670A","article-title":"Discovery of potent human lactate dehydrogenase A (LDHA) inhibitors with antiproliferative activity against lung cancer cells: Virtual screening and biological evaluation","volume":"8","author":"Li","year":"2017","journal-title":"MedChemComm"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"11886","DOI":"10.18632\/oncotarget.2620","article-title":"Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"112579","DOI":"10.1016\/j.ejmech.2020.112579","article-title":"Development of dual inhibitors targeting pyruvate dehydrogenase kinases and human lactate dehydrogenase A: High-throughput virtual screening, synthesis and biological validation","volume":"203","author":"Xiang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_155","first-page":"1479","article-title":"Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydro-genase and Either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase\/Fructose-2,6-bisphosphatase 3","volume":"36","author":"Lea","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_156","first-page":"2055","article-title":"The Molecular Mechanism and Clinical Signifi-cance of LDHA in HER2-Mediated Progression of Gastric Cancer","volume":"10","author":"Zhu","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1535-7163.MCT-08-1049","article-title":"LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer","volume":"8","author":"Xie","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/iub.1216","article-title":"Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy","volume":"65","author":"Miao","year":"2013","journal-title":"IUBMB Life"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.jmedchem.5b00168","article-title":"Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy","volume":"59","author":"Rani","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.bmcl.2013.08.060","article-title":"Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase","volume":"23","author":"Fauber","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bmcl.2015.11.025","article-title":"Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line","volume":"26","author":"Chen","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1021\/jm3014844","article-title":"Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors","volume":"56","author":"Kohlmann","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1021\/jm201734r","article-title":"Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation","volume":"55","author":"Ward","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1016\/j.bmcl.2013.04.001","article-title":"Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase","volume":"23","author":"Dragovich","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425255.2016.1145657","article-title":"Pharmacological considerations in the use of stiripentol for the treatment of epilepsy","volume":"12","author":"Verrotti","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/epi.16363","article-title":"Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study","volume":"60","author":"Rosati","year":"2019","journal-title":"Epilepsia"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","article-title":"Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient","volume":"35","author":"Kempf","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.kint.2019.06.011","article-title":"Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy","volume":"97","author":"Wyatt","year":"2020","journal-title":"Kidney Int."},{"key":"ref_169","unstructured":"(2020, August 02). Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10337-014-2818-2","article-title":"Analysis of Stiripentol Enantiomers on Several Chiral Stationary Phases: A Comparative Study","volume":"78","author":"Saleh","year":"2015","journal-title":"Chromatographia"},{"key":"ref_171","first-page":"7","article-title":"Lipase Catalysed Kinetic Resolution of Stiripentol","volume":"4","author":"Jacobsen","year":"2012","journal-title":"Int. J. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/1568026611313070008","article-title":"Medicinal Chemistry Design Principles for Liver Targeting Through OATP Transporters","volume":"13","author":"Tu","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Cox, J.H., Boily, M.-O., Caron, A., Chefson, A., Chong, O., Ding, J., Dumais, V., Gaudreault, S., Gomez, R., and Guthrie, J. (2021, January 25). Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria. Presented at the American Society of Nephrology Kidney Week Reimagined (Virtual Meeting), PO1620, October 2020. Available online: https:\/\/asn.scientificposters.com\/epsAbstractASN.cfm?id=1).","DOI":"10.1681\/ASN.20203110S1514a"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review","volume":"15","author":"Hossen","year":"2019","journal-title":"J. Adv. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2012.02.011","article-title":"Drug targeting to the diseased liver","volume":"161","author":"Poelstra","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"382184","DOI":"10.1155\/2013\/382184","article-title":"Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance","volume":"2013","author":"Mishra","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1208\/s12249-013-9999-0","article-title":"Synthesis of a Smart Gold Nano-vehicle for Liver Specific Drug Delivery","volume":"14","author":"Garg","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejpb.2007.03.022","article-title":"Poly(ethylene oxide)\u2013poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs","volume":"66","author":"Chiappetta","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1021\/nl061412u","article-title":"Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems","volume":"6","author":"Nasongkla","year":"2006","journal-title":"Nano Lett."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijbiomac.2017.12.078","article-title":"A review on chitosan and its nanocomposites in drug delivery","volume":"109","author":"Ali","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10856-013-5113-0","article-title":"Nanoparticles of deoxycholic acid, polyethylene glycol and folic acid-modified chitosan for targeted delivery of doxorubicin","volume":"25","author":"Shi","year":"2014","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"ref_182","unstructured":"Alejo-Armijo, A., Altarejos, J., Salido, S., Pina, F., and Parola, A.J. Personal communication."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/IJN.S115727","article-title":"Ligand-based targeted therapy: A novel strategy for hepatocellular carcinoma","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1166\/jnn.2017.13440","article-title":"Enhanced Cellular Uptake and Cytotoxicity of Doxorubicin by Self-Assembled Lactobionate-Phytosterol-Alginate Nanoparticles","volume":"17","author":"Wang","year":"2017","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biomaterials.2011.11.022","article-title":"Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel","volume":"33","author":"Li","year":"2012","journal-title":"Biomaterials"},{"key":"ref_186","unstructured":"Sittampalam, G.S., Grossman, A., Brimacombe, K., Arkin, M., Auld, D., Austin, C.P., Baell, J., Bejcek, B., Caaveiro, J.M.M., and Chung, T.D.Y. (2004). Interference with Fluorescence and Absorbance. Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pisc.2014.02.005","article-title":"Enzyme assays","volume":"1","author":"Bisswanger","year":"2014","journal-title":"Perspect. Sci."},{"key":"ref_188","unstructured":"Enna, S.J., and Bylund, D.B. (2007). Enzyme Assays. xPharm: The Comprehensive Pharmacology Reference, Elsevier."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/adt.2006.4.525","article-title":"A Cellular Assay for Measuring the Modulation of Glucose Production in H4IIE Cells","volume":"4","author":"Gaillard","year":"2006","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/1087057114537378","article-title":"Niemann\u2013Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy","volume":"19","author":"Yu","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-1759(88)90310-9","article-title":"A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity","volume":"115","author":"Decker","year":"1988","journal-title":"J. Immunol. Methods"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2.26.1","DOI":"10.1002\/cptx.21","article-title":"Quantification of Lactate Dehydrogenase for Cell Viability Testing Using Cell Lines and Primary Cultured Astrocytes","volume":"72","author":"Kaja","year":"2017","journal-title":"Curr. Protoc. Toxicol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/1056-8719(96)00071-8","article-title":"A rapid \u03b2-NADH-linked fluorescence assay for lactate dehydrogenase in cellular death","volume":"36","author":"Moran","year":"1996","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/B978-0-12-091302-2.50010-4","article-title":"Lactate dehydrogenase","volume":"Volume II","author":"Bergmeyer","year":"1974","journal-title":"Methods of Enzymatic Analysis"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tiv.2006.08.004","article-title":"Inactivation of lactate dehydrogenase by several chemicals: Implications for in vitro toxicology studies","volume":"21","author":"Kendig","year":"2007","journal-title":"Toxicol. In Vitro"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.06.028","article-title":"Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors","volume":"101","author":"Rupiani","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1016\/j.bmcl.2014.06.076","article-title":"Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase","volume":"24","author":"Dragovich","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/B:SCAM.0000007142.36524.58","article-title":"The mouse alanine:glyoxylate aminotransferase gene (Agxt1): Cloning, expression, and mapping to chromosome 1","volume":"25","author":"Li","year":"1999","journal-title":"Somat. Cell Mol. Genet."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1111\/j.1742-4658.2010.07882.x","article-title":"Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type I","volume":"277","author":"Salido","year":"2010","journal-title":"FEBS J."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1073\/pnas.1131968100","article-title":"Primary hyperoxaluria type 1 in the Canary Islands: A conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase","volume":"100","author":"Santana","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000085408","article-title":"Feasibility of Hepatocyte Transplantation-Based Therapies for Primary Hyperoxalurias","volume":"25","author":"Guha","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/TP.0b013e31816de49e","article-title":"Correction of Hyperoxaluria by Liver Repopulation with Hepatocytes in a Mouse Model of Primary Hyperoxaluria Type-1","volume":"85","author":"Jiang","year":"2008","journal-title":"Transplantation"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/ndt\/gfr776","article-title":"Liver cell transplantation in severe infantile oxalosis--a potential bridging procedure to orthotopic liver transplantation?","volume":"27","author":"Beck","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"F688","DOI":"10.1152\/ajprenal.00473.2011","article-title":"Hydroxyproline metabolism in mouse models of primary hyperoxaluria","volume":"302","author":"Knight","year":"2012","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrm.2015.27","article-title":"Pluripotent stem cells in disease modelling and drug discovery","volume":"17","author":"Avior","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrg3764","article-title":"Investigating human disease using stem cell models","volume":"15","author":"Sterneckert","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.scr.2015.12.014","article-title":"Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation","volume":"16","author":"Rodriguez","year":"2016","journal-title":"Stem Cell Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"101626","DOI":"10.1016\/j.scr.2019.101626","article-title":"Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene","volume":"41","author":"Salido","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_210","first-page":"297","article-title":"Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells","volume":"51","author":"Noto","year":"2009","journal-title":"Hepatology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nprot.2012.153","article-title":"Production of hepatocyte-like cells from human pluripotent stem cells","volume":"8","author":"Hannan","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00109-018-1651-8","article-title":"Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: Possible therapeutic approach for hyperoxaluria","volume":"96","author":"Belostotsky","year":"2018","journal-title":"J. Mol. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.stem.2017.01.011","article-title":"A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia","volume":"20","author":"Cayo","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_214","unstructured":"(2020, December 23). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=214103."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2169\/internalmedicine.34.502","article-title":"Characterization of the Oxidative Metabolism in Lactate Dehydrogenase A Deficiency","volume":"34","author":"Miyajima","year":"1995","journal-title":"Intern. Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/1346-8138.13516","article-title":"Hereditary lactate dehydrogenase M-subunit deficiency with late-developing pustular psoriasis-like lesions","volume":"43","author":"Takeo","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted Covalent Inhibitors for Drug Design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/fmc-2020-0118","article-title":"Covalent inhibitors: Back on track?","volume":"12","author":"Gehringer","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug\u2013target residence time model: A 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4155\/fmc.14.65","article-title":"The discovery of medicines for rare diseases","volume":"6","author":"Swinney","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-013-0164-6","article-title":"Miglustat: A Review of Its Use in Niemann-Pick Disease Type C","volume":"74","year":"2014","journal-title":"Drugs"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/1744666X.2015.1012502","article-title":"Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)","volume":"11","author":"Sabharwal","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"105504","DOI":"10.1016\/j.ejps.2020.105504","article-title":"Identification of key residues determining the binding specificity of human 4-hydroxyphenylpyruvate dioxygenase","volume":"154","author":"Liu","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S2213-8587(20)30228-X","article-title":"Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): An international, multicentre, open-label, randomised controlled trial","volume":"8","author":"Ranganath","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"112275","DOI":"10.1016\/j.ejmech.2020.112275","article-title":"A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery","volume":"195","author":"Pillaiyar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2215\/CJN.13821119","article-title":"End Points for Clinical Trials in Primary Hyperoxaluria","volume":"15","author":"Milliner","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_229","unstructured":"(2020, December 29). Biocodex Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria. NCT03819647, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819647."},{"key":"ref_230","unstructured":"Daudon, M., and Letavernier, E. (2017). Use of Stiripentol and Their Derivatives for Decreasing Urinary Oxalate Concentration in an Individual. (WO2017140658 (A1)), U.S. Patent."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/acsmedchemlett.9b00242","article-title":"Novel Therapies for Orphan Diseases","volume":"10","author":"Mellet","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-pharmtox-010818-021511","article-title":"Systems Pharmacology: Defining the Interactions of Drug Combinations","volume":"59","author":"Iyengar","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/74\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:16:07Z","timestamp":1760159767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":232,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jpm11020074"],"URL":"https:\/\/doi.org\/10.3390\/jpm11020074","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]}}}